However, not everyone in Australia knows that drugs for potency viagra australia provide not just a temporary result, but also actually help rid the body of symptoms.
Debeerdejager.co.zaJournal of the American College of Cardiology Vol. 58, No. 8, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc.
Age- and Sex-Related Differences inAll-Cause Mortality Risk Based on CoronaryComputed Tomography Angiography Findings Results From the International MulticenterCONFIRM (Coronary CT Angiography Evaluation forClinical Outcomes: An International Multicenter Registry)of 23,854 Patients Without Known Coronary Artery Disease James K. Min, MD,* Allison Dunning, MS,‡ Fay Y. Lin, MD,† Stephan Achenbach, MD,§Mouaz Al-Mallah, MD,储 Matthew J. Budoff, MD,¶ Filippo Cademartiri, MD,#Tracy Q. Callister, MD,** Hyuk-Jae Chang, MD,†† Victor Cheng, MD,‡‡ Kavitha Chinnaiyan, MD,§§Benjamin J. W. Chow, MD,储储 Augustin Delago, MD,¶¶ Martin Hadamitzky, MD,##Joerg Hausleiter, MD,## Philipp Kaufmann, MD,*** Erica Maffei, MS,# Gilbert Raff, MD,§§Leslee J. Shaw, PHD,††† Todd Villines, MD,‡‡‡ Daniel S. Berman, MD,‡‡ for theCONFIRM Investigators New York and Albany, New York; Erlangen and Munich, Germany; Detroit and Royal Oaks, Michigan;Los Angeles, California; Parma, Italy; Hendersonville, Tennessee; Seoul, Korea; Ottawa, Ontario, Canada;Zurich, Switzerland; Atlanta, Georgia; and Washington, DC We examined mortality in relation to coronary artery disease (CAD) as assessed by ⱖ64-detector row coronarycomputed tomography angiography (CCTA).
Although CCTA has demonstrated high diagnostic performance for detection and exclusion of obstructive CAD, the prognostic findings of CAD by CCTA have not, to date, been examined for age- and sex-specific outcomes.
We evaluated a consecutive cohort of 24,775 patients undergoing ⱖ64-detector row CCTA between 2005 and2009 without known CAD who met inclusion criteria. In these patients, CAD by CCTA was defined as none (0% stenosis), mild (1% to 49% stenosis), moderate (50% to 69% stenosis), or severe (ⱖ70% stenosis). CAD severitywas judged on a per-patient, per-vessel, and per-segment basis. Time to mortality was estimated using multivari- able Cox proportional hazards models.
At a 2.3 ⫾ 1.1-year follow-up, 404 deaths had occurred. In risk-adjusted analysis, both per-patient obstructive(hazard ratio [HR]: 2.60; 95% confidence interval [CI]: 1.94 to 3.49; p ⬍ 0.0001) and nonobstructive (HR: 1.60;95% CI: 1.18 to 2.16; p ⫽ 0.002) CAD conferred increased risk of mortality compared with patients without evi-dent CAD. Incident mortality was associated with a dose-response relationship to the number of coronary ves- sels exhibiting obstructive CAD, with increasing risk observed for nonobstructive (HR: 1.62; 95% CI: 1.20 to 2.19; p ⫽ 0.002), obstructive 1-vessel (HR: 2.00; 95% CI: 1.43 to 2.82; p ⬍ 0.0001), 2-vessel (HR: 2.92; 95% CI: 2.00to 4.25; p ⬍ 0.0001), or 3-vessel or left main (HR: 3.70; 95% CI: 2.58 to 5.29; p ⬍ 0.0001) CAD. Importantly,the absence of CAD by CCTA was associated with a low rate of incident death (annualized death rate: 0.28%).
When stratified by age ⬍65 years versus ⱖ65 years, younger patients experienced higher hazards for death for2-vessel (HR: 4.00; 95% CI: 2.16 to 7.40; p ⬍ 0.0001 vs. HR: 2.46; 95% CI: 1.51 to 4.02; p ⫽ 0.0003) and3-vessel (HR: 6.19; 95% CI: 3.43 to 11.2; p ⬍ 0.0001 vs. HR: 3.10; 95% CI: 1.95 to 4.92; p ⬍ 0.0001) CAD. Therelative hazard for 3-vessel CAD (HR: 4.21; 95% CI: 2.47 to 7.18; p ⬍ 0.0001 vs. HR: 3.27; 95% CI: 1.96 to5.45; p ⬍ 0.0001) was higher for women as compared with men.
Among individuals without known CAD, nonobstructive and obstructive CAD by CCTA are associated with higher rates of mortality, with risk profiles differing for age and sex. Importantly, absence of CAD is associated with a very favorable prognosis.
(J Am Coll Cardiol 2011;58:849–60) 2011 by the American College of Cardiology JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 Coronary computed tomography and Vascular Institute, Hendersonville, Tennessee; Capital angiography (CCTA) is a re- Cardiology Associates, Albany, New York; University of cently introduced noninvasive Munich, Munich, Germany; Ottawa Heart Institute, On- CAD ⴝ coronary artery imaging modality that permits tario, Canada; Henry Ford Medical Center, Detroit, Mich- accurate detection and exclusion igan; Yonsei Medical Center, Seoul, Korea, University CCTA ⴝ coronarycomputed tomography of coronary artery disease (CAD) Hospital, Zurich, Switzerland; William Beaumont Hospi- Prior studies have exam- tal, Royal Oak, Michigan; Walter Reed Army Medical CI ⴝ confidence interval ined the prognostic significance Center, Washington, DC; and University Hospital of of CAD detection by CCTA, Parma, Parma, Italy). Institutional review board approval but have been generally limited was obtained at each center. Individuals with known CAD, D-F ⴝ Diamond-Forrester to single centers and small co- as defined by prior myocardial infarction or coronary revas- horts Given the enor- cularization, were excluded from the present study analysis.
HR ⴝ hazard ratio mous evidence base on prognosis All patients were in normal sinus rhythm and were LAD ⴝ left anteriordescending artery with other cardiac imaging mo- capable of the breath hold needed for CCTA. Patients with dalities, the development of "real ⬎70 beats/min were given oral or intravenous ⴝ left circumflex world" effectiveness data that are metoprolol as per local site protocol. All centers used acquired across diverse health- intravenous metoprolol at the time of CCTA performance ⴝ left main artery care settings and populations is a to lower heart rates below 70 beats/min. If the patient's RCA ⴝ right coronaryartery requisite criterion to guide ap- heart rate did not drop below 70 beats/min, then CCTA propriate application of CCTA.
was performed at the lowest heart rate.
Fundamental to the use of Before the initiation of the scan, we prospectively col- lected information on the presence of categorical cardiac risk factors in each individual. Systemic arterial hypertensionwas defined as a documented history of high blood pressure CCTA is its ability to risk stratify younger and older women or treatment with antihypertensive medications. Diabetes and men. To date, however, age- and sex-specific outcomes mellitus was defined by diagnosis of diabetes made previ- of CCTA-identified CAD have been absent or exploratory ously by a physician and/or use of insulin or oral hypogly- To that end, we examined the predictive value of cemic agents. Dyslipidemia was defined as known but nonobstructive and obstructive CAD from a large cohort of untreated dyslipidemia or current treatment with lipid- 23,854 patients without known CAD for intermediate-term lowering medications. A positive smoking history was mortality risk and further investigated the relationship of defined as current smoking or cessation of smoking within mortality risk to CAD as stratified by age and sex.
3 months of testing. Family history of coronary heart diseasewas determined by patient query. Symptom presentation was classified into 1 of 4 categories: typical chest pain, Patients. CONFIRM (Coronary CT Angiography Evalu-
atypical chest pain, noncardiac pain, or dyspnea ation for Clinical Outcomes: An International Multicenter Scan protocol and image reconstruction. The CCTA
Registry) enrolled consecutive adults ⱖ18 years of age scans were performed on a variety of different scanner between 2005 and 2009 who underwent ⱖ64-detector row platforms (Lightspeed VCT, GE Healthcare, Milwaukee, CCTA for suspected CAD at 12 centers (Cedars Sinai Wisconsin; Somatom Definition CT, Siemens, Erlangen, Medical Center, Los Angeles, California; Harbor UCLA Germany; Somatom Definition Flash CT, Siemens). Im- Medical Center, Los Angeles, California; Tennessee Heart Dr. Min received modest speakers' bureau and medical advisory board compensation and From the *Department of Medicine, Cedars-Sinai Heart Institute, Cedars-Sinai significant research support from GE Healthcare. Dr. Achenbach received grant support Medical Center, Los Angeles, California; †Department of Medicine, Weill Cornell from Siemens and Bayer Schering Pharma and has served as a consultant for Servier. Dr.
Medical College and the New York Presbyterian Hospital, New York, New York; Al-Mallah received support from the American Heart Association, BCBS Foundation of ‡Department of Public Health, Weill Cornell Medical College and the New York Michigan, and Astellas. Dr. Budoff received modest speakers' bureau compensation from Presbyterian Hospital, New York, New York; §Department of Medicine, University GE Healthcare. Dr. Cademartiri received grant support from GE Healthcare. Dr.
of Erlangen, Erlangen, Germany; 储Department of Medicine, Wayne State University, Callister has served on the Speakers' Bureau of General Electric Healthcare. Dr.
Henry Ford Hospital, Detroit, Michigan; ¶Department of Medicine, Harbor UCLA Chinnaiyan received grant support from Bayer Pharma and Blue Cross Blue Shield Blue Medical Center, Los Angeles, California; #University Hospital of Parma, Parma, Care MI. Dr. Chow received research and fellowship support from GE Healthcare, Italy; **Tennessee Heart and Vascular Institute, Hendersonville, Tennessee; ††Divi- research support from Pfizer and AstraZeneca, and educational support from TeraRecon.
sion of Cardiology, Severance Cardiovascular Hospital, Seoul, Korea; ‡‡Department Dr. Hausleiter received a research grant from Siemens Medical Systems. Dr. Kaufmann of Imaging, Cedars Sinai Medical Center, Los Angeles, California; §§William received institutional research support from GE Healthcare and grant support from Swiss Beaumont Hospital, Royal Oaks, Michigan; 储 储Department of Medicine and Radi- National Science Foundation. Dr. Maf ei has served as a consultant to Servier and has ology, University of Ottawa, Ontario, Canada; ¶¶Capitol Cardiology Associates, received grant support from GE Healthcare. Dr. Raff received grant support from Siemens, Albany, New York; ##Division of Cardiology, Deutsches Herzzentrum Munchen, Blue Cross Blue Shield Blue Care MI, and Bayer Pharma. All other authors have reported that Munich, Germany; ***University Hospital, Zurich, Switzerland; †††Department of they have no relationships relevant to the contents of this paper to disclose.
Medicine, Emory University School of Medicine, Atlanta, Georgia; and the ‡‡‡Depart- Manuscript received December 19, 2010; revised manuscript received February 16, ment of Medicine, Walter Reed Medical Center, Washington, DC.
2011, accepted February 22, 2011.
JACC Vol. 58, No. 8, 2011 August 16, 2011:849 – 60 Age- and Sex-Related Prognosis by CCTA aging of a test bolus of contrast was performed at 2 mm was highly calcified, 2-dimensional oblique images were also superior to the take-off of the left main coronary artery for visualized without maximal-intensity projection (i.e., 0.625- precise timing of contrast injection. During the CCTA to 0.75-mm isotropic voxel resolution) or multiplanar re- acquisition, 80 to 140 ml of iodinated contrast (Isovue 370, formats with cross-sectional views to minimize partial- Bracco Diagnostics, Princeton, New Jersey; Omnipaque, volume averaging artifact of calcium.
GE Healthcare, Princeton, New Jersey; Visipaque, GE Plaque severity was graded on a per-patient, per-vessel, Healthcare, Princeton, New Jersey; or Imeron 350; Bracco and per-segment level. Per-patient maximal plaque severity Atlana Pharma, Konstanz, Germany) was injected, followed was defined by the maximal intraluminal stenosis in any of by a 50-ml saline flush. Contrast timing was performed to the coronary segments at the ⱖ50% stenosis or ⱖ70% optimize uniform contrast enhancement of the coronary stenosis threshold.
arteries. The scan parameters were as follows: 64 ⫻ 0.625/ For purposes of classification for per-vessel analyses, we 0.750-mm collimation, tube voltage 100 or 120 mV, effec- considered 4 arterial territories: left main artery (LM), left tive 400 to 650 mA. Dose reduction strategies—including anterior descending artery (LAD), left circumflex artery electrocardiogram-gated tube current modulation, reduced (LCx), and right coronary artery (RCA). Obstructive CAD tube voltage, and prospective axial triggering—were used in the diagonal branches, obtuse marginal branches, and whenever feasible. Estimated radiation dose for CCTA posterolateral branches was considered as part of the LAD, ranged from 3 to 18 mSv.
LCx, and RCA system, respectively. The posterior descend- Helical or axial scan data were obtained with retrospective ing artery was considered as part of the RCA or LCx or prospective electrocardiogram gating, respectively. Im- system, depending on the coronary artery dominance. A ages were reconstructed immediately after completion of the ⱖ50% stenosis in the LM was considered obstructive in all scan to identify motion-free coronary artery images. Opti- models. Per-vessel CAD severity was defined by ⱖ50% mal phase reconstruction was assessed by comparison of stenosis or ⱖ70% stenosis in 0, 1, 2, or 3 coronary artery different phases, if available, and the phase with the least amount of coronary artery motion was chosen for analysis.
Per-segment analysis was judged for individual coro- Multiple phases were utilized for image interpretation if nary artery segments that included a 16-segment model, minimal coronary artery motion was different for different as we have previously described Similarly, the incre- arteries. CCTAs were evaluated by an array of post- mental hazards of CAD for increasing numbers of processing imaging techniques, including axial, multiplanar segments were calculated as clinical coronary artery reformat, maximum-intensity projection, and short-axis plaque scores, as we have previously described A cross-sectional views. In all individuals, irrespective of segment involvement score was calculated as the total image quality, every arterial segment was scored in an number of coronary artery segments exhibiting plaque, intent-to-diagnose fashion. If a coronary artery segment was irrespective of the degree of luminal stenosis within each uninterpretable despite these multiple techniques, the non- segment (minimum ⫽ 0; maximum ⫽ 16). A segment evaluable segment was scored similarly to the most proximal stenosis score was used as a measure of overall coronary segment that was evaluable.
artery plaque extent. Each individual coronary segment Noninvasive coronary artery analysis by CCTA. All
was graded as having no to severe plaque (i.e., scores from scans were analyzed by Level III– equivalent cardiologists 0 to 3) based on extent of obstruction of coronary luminal with experience interpreting several thousand CCTA scans.
diameter. Then the extent scores of all 16 individual Interpretation of CCTA was uniform across all study sites, segments were summed to yield a total score ranging with coronary segments visually scored for the presence of from 0 to 48. We further examined risk in association coronary plaque using a 16-segment coronary artery model with any severe proximal stenosis in the LAD, LCx, or in an intent-to-diagnose fashion. In each coronary artery RCA vessels. Finally, we examined risk for any plaque segment, coronary atherosclerosis was defined as tissue within the LM.
structures ⬎1 mm2 that existed either within the coronary Follow-up. The primary endpoint was time to death from
artery lumen or adjacent to the coronary artery lumen that all causes. Follow-up procedures were approved by all study could be discriminated from surrounding pericardial tissue, centers' institutional review boards. Death status for non- epicardial fat, or the vessel lumen itself. Coronary athero- U.S. centers was gathered by clinical visits, telephone sclerotic lesions were quantified for stenosis by visual esti- contacts, and questionnaires sent by mail, with verification mation. Luminal-diameter stenosis severity was scored as of all reported events by hospital records or direct contact none (0% luminal stenosis), mild (1% to 49% luminal with a patient's attending physician. Death status for U.S.
stenosis), moderate (50% to 69% luminal stenosis), or severe centers was ascertained either by query of the Social Security (ⱖ70% luminal stenosis). Percent obstruction of coronary Death Index or by scripted interview by experienced physi- artery lumen was based on a comparison of the luminal cian and/or nurse study investigators.
diameter of the segment exhibiting obstruction to the Statistical analysis. SPSS version 12.0 (SPSS Inc., Chi-
luminal diameter of the most normal-appearing site imme- cago, Illinois) and SAS version 9.2 (SAS Institute, Cary, diately proximal to the plaque. In instances in which plaque North Carolina) were used for all statistical analyses.
JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 Demographics of the Entire Registry and Study Cohort Demographics of the Entire Registry and Study Cohort Excluded Patients Family history of premature CAD History of PAD/CVD Pre-test CAD likelihood† Values are mean ⫾ SD or n (%). *p value for differences in percentages for study cohort versus excluded patients. †Typicality of chest pain andpre-test likelihood of CAD missing in 518 patients.
CAD ⫽ coronary artery disease; CVD ⫽ cardiovascular disease; PAD ⫽ peripheral arterial disease.
Categorical variables are presented as frequencies and ratio (HR) and 95% confidence interval (CI) were calcu- continuous variables as mean ⫾ SD. Variables were lated from the Cox models. A 2-tailed p ⬍ 0.05 was compared with chi-square statistic for categorical vari- considered statistically significant.
ables and by Student unpaired t test for continuousvariables. Time to death from all causes and death rates were calculated using univariable Cox proportional haz-ards models. In each case, the proportional hazards Clinical characteristics of the study cohort. Amongst
assumption was met. Adjusted models were also devised 27,125 consecutive patients undergoing CCTA at 12 cen- including multivariable stepwise models adjusting for ters for whom per-segment CAD data were available, 2,350 baseline demographics, cardiac risk factors, typicality of patients with a history of myocardial infarction, coronary angina, and pre-test likelihood of obstructive CAD.
revascularization, and cardiac transplant were excluded. The Adjusted models were also developed to test first-order final analysis cohort consisted of 24,775 patients. Follow-up interactions related to age, sex, and study site. A hazard was obtained for 23,854 patients (96.3%), with 921 patients Clinical Characteristics of Study Group Stratified by Normal, Nonobstructive, and Obstructive CAD by CCTA Clinical Characteristics of Study Group Stratified by Normal, Nonobstructive, and Obstructive CAD by CCTA Nonobstructive CAD p Value for Trend Family history of premature CAD Chest pain typicality* Pre-test CAD likelihood Values are n (%). *Chest pain typicality and pre-test likelihood of CAD missing in 2,867 patients.
CAD ⫽ coronary artery disease; CCTA ⫽ coronary computed tomography angiography.
JACC Vol. 58, No. 8, 2011 August 16, 2011:849 – 60 Age- and Sex-Related Prognosis by CCTA CCTA findings among those who lived versus died. As
Clinical Characteristics Associated With Mortality Clinical Characteristics Associated With Mortality compared with patients who were alive at follow-up, pa- Univariate HR (95% CI) tients who died had significantly more severe coronary artery 1.09 (1.08–1.10) stenoses in the majority of coronary segments 1.05 (0.87–1.28) Impact of per-patient, per-vessel, and per-segment CAD
2.13 (1.71–2.65) severity by CCTA on death from all causes. In both
1.93 (1.57–2.37) univariable as well as multivariable Cox regression anal- 0.71 (0.59–0.87) ysis considering age and CAD risk factors, all-cause 1.47 (1.17–1.85) mortality was predicted by maximal per-patient nonob- Family history of premature CAD 1.11 (0.90–1.36) Pre-test CAD likelihood 1.20 (0.996–1.45) structive and obstructive CAD, whether using a defini-tion of obstructive CAD as 1% to 49% or 1% to 69% CAD ⫽ coronary artery disease; CI ⫽ confidence interval; HR ⫽ hazard ratio.
By both univariable and multivariable Cox models, per- lost to follow-up. The study cohort was middle-aged (age vessel assessment of obstructive CAD demonstrated a dose- 57 ⫾ 13 years, 54% male) with a high prevalence of response relationship for increased hazards for death for cardiovascular risk factors and symptoms. They presentedwith typical or atypical angina in the majority of cases, with 1-vessel, 2-vessel, 3-vessel, or LM CAD the majority of individuals having intermediate or high Similarly, in both univariable and multivariable Cox regres- pre-test likelihood of obstructive CAD. Excluded patients sion analysis, on a per-segment basis, higher rates of had a higher pre-test likelihood of CAD mortality were associated with greater numbers of segments Clinical characteristics associated with CAD and mortality.
with plaque, with stenosis-adjusted segments with plaque, Survival was examined after a mean follow-up of 2.3 ⫾ 1.1 with any severe proximal stenosis, and with any plaque years (median 2.1 years; interquartile range: 1.5 to 3.1 years), at which point 404 deaths were recorded. Increasing Sixty-six deaths (0.65%) occurred in patients without severity of CAD was associated with male sex, diabetes, evident CAD by CCTA (n ⫽ 10,146; 43%), resulting in a hypertension, dyslipidemia, family history of CAD, current mean annualized death rate of 0.28%. In additional analyses smoking, typical angina, and high pre-test likelihood of of patients undergoing CCTA followed for ⱖ4 years (n ⫽ CAD (p ⬍ 0.0001 for all) In univariable Cox 1,816) without evidence by CCTA (n ⫽ 1,009), annualized proportional hazards models, increased hazard for death was death rates were 0.22%.
associated with advanced age, diabetes, hypertension, un- Age- and sex-stratified impact of CCTA-visualized CAD
treated dyslipidemia, and current smoking, but not family on death from all causes. Individuals ⬍65 years of age had
history of CAD or pre-test CAD likelihood lower pre-test probability of CAD than those ⱖ65 years of Coronary Artery Stenosis Severity by Segment For Individuals Who Lived Versus Died Coronary Artery Stenosis Severity by Segment For Individuals Who Lived Versus Died Alive (n ⴝ 23,450) Diagonal artery 1 Diagonal artery 2 Obtuse marginal 1 Obtuse marginal 2 Right coronary artery Posterior descending artery CAD ⫽ coronary artery disease; LAD ⫽ left anterior descending artery; LCx ⫽ left circumflex artery; LM ⫽ left main artery; PL ⫽ posterolateral.
JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 Per-Vessel, and Adjusted Hazard Ratios Mortality All-Cause Per-Patient, Mortality by Stenosis Level Per-Vessel, and Per-Segment Analysis by Obstructive CAD at the 50% and 70% Stenosis Level Obstructive CAD (Defined at 50% Level) Obstructive CAD (Defined at 70% Level) Per-patient analysis Nonobstructive CAD 2.88 (2.15–3.86) 1.60 (1.18–2.16) 3.29 (2.50–4.34) 1.76 (1.32–2.34) 6.05 (4.58–7.99) 2.60 (1.94–3.49) 8.11 (6.00–11.0) 3.13 (2.27–4.31) Per-vessel analysis 2.88 (2.15–3.86) 1.62 (1.20–2.19) 3.30 (2.50–4.34) 1.77 (1.33–2.36) 1-vessel obstructive 4.12 (2.96–5.72) 2.00 (1.43–2.82) 5.67 (3.97–8.10) 2.35 (1.62–3.42) 2-vessel obstructive 6.93 (4.82–9.96) 2.92 (2.00–4.25) 11.40 (7.56–17.2) 3.94 (2.57–6.04) 3-vessel or left main 10.52 (7.50–14.7) 3.70 (2.58–5.29) 15.52 (10.1–23.9) 5.27 (3.36–8.27) Per-segment analysis Segment involvement score 1.22 (1.18–1.25) 1.10 (1.06–1.13) (per segment involved) Segment stenosis score (per 1.12 (1.11–1.14) 1.06 (1.05–1.08) segment severity) Any severe proximal stenosis 4.01 (3.12–5.17) 2.15 (1.66–2.78) Any left main stenosis 2.51 (2.01–3.13) 1.45 (1.15–1.82) NA ⫽ not applicable; other abbreviations as in age (pre-test probability low 34% vs. 16%; intermediate 60% hazards for mortality if 2- or 3-vessel/LM obstructive CAD vs. 67%, high 6% vs. 17%, chi-square p ⬍ 0.0001). As was present than patients ⱖ65 years of age, with similar compared with individuals without CAD within respective rates of death for nonobstructive and 1-vessel obstructive age groups, patients ⬍65 years of age experienced higher Unadjusted All-Cause 3-Year Kaplan-Meier Survival by the Maximal Per-Patient Presence of None, Nonobstructive, and Obstructive CAD Patients with nonobstructive coronary artery disease (CAD) had an intermediate prognosis that resides between patients with no evident CAD and those with obstructive CAD.
JACC Vol. 58, No. 8, 2011 August 16, 2011:849 – 60 Age- and Sex-Related Prognosis by CCTA Unadjusted All-Cause 3-Year Kaplan-Meier Survival by the Presence, Extent, and Severity of CAD by CCTA Note the dose-response relationship of mortality to increasing numbers of vessels with obstructive coronary artery disease (CAD).
CCTA ⫽ coronary computed tomography angiography.
Female patients referred to CCTA had higher pre-test and CAD (p ⫽ 0.21) and sex and CAD (p ⫽ 0.76) did not probability of CAD than men. Differences in pre-test reveal significant relationships.
likelihood for obstructive CAD existed by sex, with maleand female patients presenting with low (pre-test probabil- ity low 35% vs. 24%, intermediate 56% vs. 68%, and high9% vs. 9%; p ⬍ 0.0001). As compared with individuals These results of the CONFIRM registry represent the first without CAD within respective sexes, women experienced prospective international multicenter data to relate CCTA- higher hazards for mortality for 3-vessel or LM obstructive determined extent and severity of CAD to all-cause mor- CAD than males, with similar rates of death for nonob- tality and demonstrate the independent prognostic value of structive, 1-vessel, and 2-vessel obstructive CAD both obstructive as well as nonobstructive CAD by CCTA.
Importantly, this study had adequate sample size and was When stratified by both age and sex, differences in adequately powered (beta ⬎0.90, alpha ⬍0.001) to permit multivariable risk-adjusted hazards for mortality were ob- differential risk stratification of individuals as categorized by served for nonobstructive and 1-, 2-, and 3-vessel or LM age group and sex. The findings of this study should be obstructive CAD Tests for interactions of age considered widely generalizable, given the high number of Versus > All-Cause All-Cause Mortality for Patients <65 Versus >65 Years of Age
Age <65 Yrs
3-vessel disease or left main disease Abbreviations as in
JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by Presence, Extent, and Severity of CAD by CCTA as Stratified by Age <65 or >65 Years
Although rates of mortality in relationship to CAD extent are lower in patients age ⬍65 years (A), patients age ⬍65 years with 2- and 3-vessel CAD experience a higherrelative rate of mortality referenced to patients age ⬍65 years with no CAD in comparison with patients age ⱖ65 years with 2- and 3-vessel CAD referenced to patientsage ⱖ65 years with no CAD (B). Abbreviations as in JACC Vol. 58, No. 8, 2011 August 16, 2011:849 – 60 Age- and Sex-Related Prognosis by CCTA Adjusted Hazard Ratios for All-Cause Mortality for Female Versus Male Patients Adjusted Hazard Ratios for All-Cause Mortality for Female Versus Male Patients 3-vessel/left main disease Abbreviations as in enrolled subjects; the inclusion of numerous clinical sites assessment The current data suggest that use of the within North America, Europe, and Asia; and the unifor- D-F method is insufficient for this purpose and should not mity of study results across sites.
be used solely as a judge of risk.
Despite increasing adoption of CCTA for clinical use in We also identified a utility of nonobstructive CAD individuals with suspected CAD, limited "real world" effec- detection for risk stratification of individuals at height- tiveness evidence still exists to support the prognostic ened risk of incident death. Indeed, individuals with significance of CAD findings as detected by current- nonobstructive CAD (HR: 1.62; 95% CI: 1.08 to 2.43) generation ⱖ64-detector row CCTA. Furthermore, prior by CCTA experienced a mortality risk that was similar to studies to date that have examined the ability of CCTA that of those with obstructive 1-vessel CAD (HR: 1.75; findings to stratify risk have been generally limited to single 95% CI: 1.12 to 2.72). These data corroborate our prior centers with relatively small sample sizes. We previously studies using older generation electron beam CT tech- reported the predictive value of CCTA measures of CAD nology, where the presence of nonobstructive CAD extent and severity in a 2-center study of 5,330 consecutive conferred similar risk as 1-vessel obstructive CAD. These patients, but data were limited in that population to vessel- findings have important implications, as patients with based analyses, and the prognostic potential of segment- nonobstructive CAD comprise the majority of patients based as well as nonobstructive CAD detection by CCTA who experience myocardial events and for whom func- could not be examined In a separate analysis, we tional stress testing aimed at detecting flow-limiting reported the prognostic significance of CCTA-identified coronary artery stenoses would be expectedly negative CAD findings in 1,256 consecutive patients with suspected Given a robust evidence base demonstrating the CAD for the prediction of major adverse cardiac events highly salutatory effect of primary prevention of CAD Although we noted a 16- to 17-fold increased risk in events in at-risk individuals, future studies should be myocardial events in patients with obstructive CAD, the performed to determine the effect of aggressive medical observed event rates were low (0.6% to 1.8%) and the therapy and lifestyle modification for individuals with follow-up duration shorter than in the present study. In this CCTA-identified nonobstructive CAD.
regard, the current data extend prior studies by examining We recently reported the results of an exploratory CCTA findings of CAD in a large consecutive cohort analysis of 1,127 consecutive patients with suspected comprising multiple international sites that was evaluated by CAD undergoing 16-detector row CCTA identified to current-generation computed tomography (CT) technology have only obstructive CAD. In this study, 490 patients for measures of both obstructive and nonobstructive CAD.
were identified as having nonobstructive CAD (as de- That CCTA can effectively risk stratify individuals without fined by maximal ⬍50% luminal diameter stenosis at the known CAD should be invaluable for guiding the develop- per-patient level) In 4-year follow-up, the number ment of clinical practice guidelines and appropriate use of coronary segments exhibiting nonobstructive CAD was predictive of incident death in women but not in One notable finding in our study was that although the men. This study expands on these prior published results pre-test likelihood of obstructive CAD—as estimated by by using a study cohort of sufficient magnitude to the Diamond-Forrester (D-F) tabular method—was highly examine the presence of nonobstructive CAD at the predictive of the presence of obstructive CAD by CCTA, it per-patient level. The present data corroborate the prior did not demonstrate predictive value for incident death in data, revealing a prognostic value for per-patient nonob- this large cohort of patients with suspected CAD. At structive CAD detection in women but not in men.
present, clinicians commonly use D-F pre-test estimations Further, the current study extends prior study results by of likelihood of obstructive CAD as a metric to determine demonstration that 1-vessel obstructive CAD also con- whether patients would benefit from noninvasive testing.
fers heightened risk of death in women but not in men.
Because global clinical risk scores are currently lacking for Numerous possibilities exist to explain these findings.
symptomatic stable individuals with suspected CAD, many Women in our study had lower rates of both obstructive have also adopted use of the D-F method for "risk" and nonobstructive CAD in contrast to their male
JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 Unadjusted All-Cause 3-Year Kaplan-Meier Survival by Presence, Extent, and Severity of CAD by CCTA as Stratified by Sex Although rates of mortality in relationship to CAD extent are lower in women, women with 3-vessel CAD experience a higher relative rate of mortality referenced to women with no CAD (A) in comparison with men with 3-vessel CAD referenced to men with no CAD (B). Abbreviations as in counterparts, despite higher estimated pre-test probabil- to "exclusion" of cardiac causes of symptoms in women, ity. This generally lower prevalence of disease in women despite a higher rate of hospitalization for angina as has been historically associated with lower rates of compared with men It remains possible in this invasive coronary angiographic evaluation and often leads open-label study that the identification of nonobstructive JACC Vol. 58, No. 8, 2011 August 16, 2011:849 – 60 Age- and Sex-Related Prognosis by CCTA Multivariable Adjusted Hazard Ratios for All-Cause Mortality as Stratified by Age and Sex Multivariable Adjusted Hazard Ratios for All-Cause Mortality as Stratified by Age and Sex Age <65 Yrs
3-vessel/left main disease Abbreviations as in disease in women led clinicians to pursue alternative future studies examining the risk of major adverse cardiac noncardiac diagnoses for symptoms, and lack of aggressive events in relation to CCTA findings. Further, referral bias due treatment for these CAD findings resulted in heightened risk of to excluded patients and treatment of individuals based on incident death. Future studies should carefully evaluate this CCTA findings of CAD are unknown in this open-label potential explanation and should determine the effect of multicenter registry. Whether percutaneous or surgical coro- primary prevention with aggressive medical therapy in this nary revascularization, enhanced medical therapy, or lifestyle modifications occurred after CCTA performance is unknown.
In the present study, we also observed differential risk We have previously demonstrated that CAD risk factor control stratification of CCTA-identified CAD findings by age is improved in direct relation to the extent and severity of groups. Although risk of all-cause death increased in a CCTA CAD findings, but whether this affects mortality has generally linear fashion for patients ⱖ65 years of age for not been explored. For proper evaluation of this issue, large- extent and severity of CAD, patients ⬍65 years of age scale trials with prescribed treatment algorithms will be neces- experienced a more abrupt increase in risk of death associ- sary. In addition, our analysis entailed the evaluation of CAD ated with 2- and 3-vessel or LM CAD over nonobstructive by semiquantitative visual analysis rather than by volumetric or 1-vessel CAD. Although numerous explanations exist to quantification of plaque. At the time of initiation of the study account for these findings, it may be that younger patients (and to date), no automated validated software existed for with greater extent and severity of CAD represent a cohort automatic quantification of plaque or stenosis severity. Instead, with more aggressive forms of atherosclerosis than their this multicenter study used experienced level III CCTA older counterparts, thus resulting in a higher risk than for imagers and used a uniform grading system that is most older patients with more insidious atherosclerosis.
commonly used in daily clinical practice. Finally, this study Finally, we observed a very low rate of death for individuals examined only patients without history of known CAD. As without evident CAD by CCTA. This low rate of death such, whether these findings can be extrapolated to those with validates the favorable prognosis that has been uniformly prior myocardial infarction or coronary revascularization needs observed in prior smaller registries and emphasizes a clinical to be tested in future studies.
value of CCTA for identification of individuals in whom nofurther additional testing and/or therapy is necessary or indi-cated Using older generation electron beam CT technology, Ostrom et al. demonstrated that this very lowdeath rate continues to persist for up to 7 years from the time In the large, prospective, international, multicenter CONFIRM of the CCTA, and the present results are in direct accordance registry, extent and severity of CAD by CCTA successfully with those findings. Similarly, the long-term ⱖ4-year progno- identifies individuals at heightened risk for all-cause mor- sis of patients in the present registry without evident CAD by tality. Presence of both obstructive and nonobstructive CCTA was extremely favorable, with a 0.22% annualized CAD by CCTA on a per-patient, per-vessel, and per- death rate. These results may inform clinicians on the need for segment basis portends worsened prognosis, with differen- repeat testing in patients with normal CCTA and suggest a tial risk noted between sex and age groups. Importantly, "warranty" period of a normal CCTA to last at least 4 years.
individuals without evident CAD by CCTA are at very low Study limitations. Although this study addresses many of
risk of death.
the shortcomings of prior analyses examining the prognosticvalue of CCTA, it is not without limitations. For the present Reprint requests and correspondence: Dr. James K. Min, De-
analysis, the major endpoint was all-cause mortality. Other partments of Medicine, Imaging and Biomedical Sciences, "softer" endpoints—including myocardial infarction, unstable Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, 8700 angina, or CAD-related hospitalization—were not included in Beverly Blvd, S. Taper Bldg, Room 1258, Los Angeles, CA this initial analysis. Although use of all-cause death mitigates ascertainment bias, it will nevertheless be important to perform JACC Vol. 58, No. 8, 2011 Age- and Sex-Related Prognosis by CCTA August 16, 2011:849 – 60 coronary atherosclerosis, and left ventricular ejection fraction. J AmColl Cardiol 2010;55:1017–28.
1. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 12. van Werkhoven JM, Schuijf JD, Gaemperli O, et al. Incremental 64-multidetector row coronary computed tomographic angiography prognostic value of multi-slice computed tomography coronary an- for evaluation of coronary artery stenosis in individuals without known giography over coronary artery calcium scoring in patients with coronary artery disease: results from the prospective multicenter suspected coronary artery disease. Eur Heart J 2009;30:2622–9.
ACCURACY (Assessment by Coronary Computed Tomographic 13. van Werkhoven JM, Schuijf JD, Gaemperli O, et al. Prognostic value Angiography of Individuals Undergoing Invasive Coronary Angiogra- of multislice computed tomography and gated single-photon emission phy) trial. J Am Coll Cardiol 2008;52:1724 –32.
computed tomography in patients with suspected coronary artery 2. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of disease. J Am Coll Cardiol 2009;53:623–32.
coronary angiography by 64-row CT. N Engl J Med 2008;359:2324–36.
14. Pundziute G, Schuijf JD, Jukema JW, et al. Prognostic value of multislice 3. Meijboom WB, Meijs MF, Schuijf JD, et al. Diagnostic accuracy of computed tomography coronary angiography in patients with known or 64-slice computed tomography coronary angiography: a prospective, suspected coronary artery disease. J Am Coll Cardiol 2007;49:62–70.
multicenter, multivendor study. J Am Coll Cardiol 2008;52:2135– 44.
15. Shaw LJ, Min JK, Narula J, et al. Sex differences in mortality 4. Min JK, Shaw LJ, Devereux RB, et al. Prognostic value of multide- associated with computed tomographic angiographic measurements of tector coronary computed tomographic angiography for prediction of obstructive and nonobstructive coronary artery disease. Circ Cardio- all-cause mortality. J Am Coll Cardiol 2007;50:1161–70.
vasc Imaging 2010;3:473– 81.
5. Min JK, Lin FY, Dunning AM, et al. Incremental prognostic 16. Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance significance of left ventricular dysfunction to coronary artery disease of dyspnea in patients referred for cardiac stress testing. N Engl J Med detection by 64-detector row coronary computed tomographic angiog- raphy for the prediction of all-cause mortality: results from a two- 17. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical centre study of 5330 patients. Eur Heart J 2010;31:1212–9.
diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350–8.
6. Min JK, Feignoux J, Treutenaere J, Laperche T, Sablayrolles J. The 18. Diamond GA, Forrester JS, Hirsch M, et al. Application of condi- prognostic value of multidetector coronary CT angiography for the tional probability analysis to the clinical diagnosis of coronary artery prediction of major adverse cardiovascular events: a multicenter obser- disease. J Clin Invest 1980;65:1210 –21.
vational cohort study. Int J Cardiovasc Imaging 2010;26:721– 8.
19. Falk E. Morphologic features of unstable atherothrombotic plaques 7. Shaw LJ, Berman DS, Hendel RC, Borges NS, Min JK, Callister TQ.
underlying acute coronary syndromes. Am J Cardiol 1989;63:114E–20E.
Prognosis by coronary computed tomographic angiography: matched 20. Shaw LJ, Shaw RE, Merz CN, et al. Impact of ethnicity and gender comparison with myocardial perfusion single-photon emission com- differences on angiographic coronary artery disease prevalence and puted tomography. J Cardiovasc Comput Tomogr 2008;2:93–101.
in-hospital mortality in the American College of Cardiology- 8. Hadamitzky M, Freissmuth B, Meyer T, et al. Prognostic value of National Cardiovascular Data Registry. Circulation 2008;117: coronary computed tomographic angiography for prediction of cardiac 1787– 801.
events in patients with suspected coronary artery disease. J Am Coll 21. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and Cardiol Img 2009;2:404 –11.
stroke statistics—2009 update: a report from the American Heart 9. Hadamitzky M, Hein F, Meyer T, et al. Prognostic value of coronary Association Statistics Committee and Stroke Statistics Subcommittee.
computed tomographic angiography in diabetic patients without Circulation 2009;119:480 – 6.
known coronary artery disease. Diabetes Care 2010;33:1358 – 63.
22. Ostrom MP, Gopal A, Ahmadi N, et al. Mortality incidence and the 10. Hadamitzky M, Meyer T, Hein F, et al. Prognostic value of coronary severity of coronary atherosclerosis assessed by computed tomography computed tomographic angiography in asymptomatic patients. Am J angiography. J Am Coll Cardiol 2008;52:1335– 43.
Cardiol 2010;105:1746 –51.
11. Chow BJ, Wells GA, Chen L, et al. Prognostic value of 64-slice Key Words: atherosclerosis y computed tomography y coronary disease
cardiac computed tomography severity of coronary artery disease, y nonobstructive y prognosis.
EDUCATIONAL OBJECTIVE: Readers will manage psoriasis on the basis of its type and severity JENNIFER VILLASEÑOR-PARK, MD, PhD DAVID WHEELER, BS LISA GRANDINETTI, MD, FAAD University of Pittsburgh, Department of Dermatology, University of Pittsburgh School of Medicine, University of Pittsburgh, Department of Dermatology, Pittsburgh, PA Psoriasis:
82 JEMS MARCH 2006 Story by Jay Carter, MSEE, MD, FACEP, & David Enzman, NREMT-P; Photos by Bruce Graham, NREMT-P, Hudson EMS Operations Manager Extrication of patients from motor vehicle accidents is usually well covered in EMTcourses, and EMS personnel gain ex- pertise in this component of rescue operations—many calls, many scenarios, much extricationexperience—early on in their careers. But a crewfrom Hudson (Ohio) EMS (HEMS), with acombined EMS experience totaling more than100 years, responded to a call that presented aunique situation.